Oxycodone/Naloxone Stada (Naloxone, Oxycodone)

Oxycodone, the active ingredient in Oxycodone/Naloxone Stada, is an opioid analgesic presented as a combination tablet for oral use. It treats moderate to severe pain in adult patients when an opioid is required. Naloxone, the second active ingredient, is an opioid antagonist included to reduce opioid‑induced constipation and bowel dysfunction.

GNH USA supplies Oxycodone/Naloxone Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone/Naloxone Stada is used in the management of pain conditions that involve opioid pathways. It provides balanced analgesia while mitigating opioid‑related gastrointestinal effects. - Chronic cancer pain: improves pain control while reducing constipation risk. - Post‑operative pain: offers strong analgesia after major surgery with a lower incidence of bowel dysfunction. - Severe chronic non‑cancer pain: delivers long‑term relief for patients who need high‑potency opioids.

Adverse reactions may occur with Oxycodone/Naloxone Stada and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements despite naloxone. - Dizziness: light‑headed sensation, especially on standing. - Somnolence: increased sleepiness or fatigue. - Dry mouth: reduced salivary flow. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Hepatic impairment: elevated liver enzymes or liver dysfunction. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Opioid dependence or withdrawal: signs of physical dependence with abrupt discontinuation.

When prescribing Oxycodone/Naloxone Stada, clinicians should consider several safety aspects. - Assess pain severity: confirm that opioid therapy is appropriate for the patient. - Monitor for respiratory depression: especially during initiation and dose escalation. - Evaluate liver function: naloxone metabolism is hepatic; adjust if impaired. - Caution in the elderly: increased sensitivity to sedative and hypotensive effects. - Avoid concurrent CNS depressants: limit additive sedation or respiratory risk. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture.

Oxycodone/Naloxone Stada can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - CNS depressants: alcohol, barbiturates, or other sedatives increase risk of sedation and respiratory compromise. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise oxycodone plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce analgesic effect. - Diuretics: may enhance hypotensive response. - Anticholinergics: can worsen constipation despite naloxone's protective effect.